9.280USD-2.26%Mkt Cap: 628.70M USDP/E: 22.63Last update: 2026-05-22
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which compr…
Industry Peers
Medical Devices152.25BUSDP/E 24.5
85.88BUSDP/E 24.2
53.45BSEKP/E 22.7
53.33BSEKP/E 98.9
52.13BDKKP/E 22.1
38.61BEURP/E 18.3
23.15BSEK—
22.25BEURP/E 23.4
loading…
Indicators:|
Key Statistics
Company
Market Cap628.70M USD
Enterprise Value941.21M USD
Revenue (TTM)576.30M USD
Gross Profit388.16M USD
Net Income (TTM)22.73M USD
Revenue/Share8.609 USD
Last Price9.280 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees940
CountryUS
SectorHealthcare
IndustryMedical Devices
ISIN—
Valuation
P/E (Trailing)22.63
P/E (Forward)10.46
PEG1.39
EV/EBITDA11.63
EV/Revenue1.63
P/S1.12
P/B3.40
EPS (TTM)0.41
EPS (Forward)0.91
52W Range
5.81064% of range11.25
52W High11.25 USD
52W Low5.810 USD
Profitability
Gross Margin68.33%
Oper. Margin6.73%
EBITDA Margin14.04%
Profit Margin4.00%
ROE12.35%
ROA3.33%
Growth
Revenue Growth6.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF74.67M USD
CapEx (TTM)2.56M USD
FCF Margin10.99%
FCF Yield10.07%
Net Debt252.57M USD
Net Debt/EBITDA3.12
Balance Sheet
Debt/Equity1.60
Current Ratio1.69
Quick Ratio1.06
Book Value/Sh2.793 USD
Cash/Share0.5290 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)14.80 USD
Target Range14.00 USD – 16.00 USD
# Analysts5
Ownership
Shares Out.67.75M
Float33.64M
Insiders11.26%
Institutions78.29%
Short Interest
Short Ratio3.3d
Short % Float3.16%
Short % Out.2.16%
Shares Short1.47M
Short (prev mo.)1.53M
Technical
SMA 509.700 (-4.3%)
SMA 2008.047 (+15.3%)
Beta0.72
S&P 52W Chg28.31%
Avg Vol (30d)535.91K
Avg Vol (10d)553.50K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—